The S&P 500 had a good week due to the impressive start of Q1 earnings and favorable inflation data. In March, the consumer price index rose 5%, lower than the previous month's 6%, and met economists' expectations.
Inovio to Plunge Ahead of Earnings Report
2022-12-15 • Updated
About the company
Inovio Pharmaceuticals Inc (INO) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines to treat and prevent various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology.
When the pandemic roiled America in 2020, COVID stocks, including Inovio, gained momentum. Robinhood named Inovio as one of the top 10 most traded stocks on its platform in April 2020, putting Inovio in line with Microsoft (MSFT), Disney (DIS), and Tesla (TSLA). However, the company hasn't been successful in developing a vaccine.
Initially, Inovio announced plans to develop COVID-19 vaccines targeting the recently discovered Omicron variant, which boosted the stock. However, in March 2022, Inovio stated that it paused the development of its phase 3 INO-4800 trial.
The company announced an update of the strategy on the Q1, 2022 earnings call and its more recent CEO presentation at Jefferies 2022 Global Healthcare Conference in June 2022.
CEO Shea described the situation as follows:
"As the COVID-19 pandemic evolves towards the endemic phase, the need for booster vaccines to protect against severe illness and death represents a growing and strategic opportunity. In light of this, we now believe that Inovio can have the greatest impact and serve the most pressing public health needs by focusing on the COVID vaccine in our heterologous booster strategy".
Inovio Pharmaceuticals Inc will release the Q2 2022 financial results on August 9, after the market close (23:30 GMT+3). Following the release, INOVIO will host a live conference call to discuss the financial statement and provide a general business update.
What to expect?
The recent history shows the stock usually falls ahead of earnings reports on expectations of worse-than-expected results. Moreover, after the two latest reports (May 10, 2022, and March 01, 2022), the price opened lower with a gap and returned to growth the next day.
In Q2 2022, the company didn't succeed in drug development, and actual financial results will likely underperform the expectations. Therefore, FBS analysts believe the stock might plunge ahead of the report.
INO, H4 chart
Resistance: $2.27, $2.35
Support: $1.94, $1.83, $1.73
On Friday, July 29, the stock dropped out of the descending channel despite the growth of the US stock indices, highlighting its weakness ahead of the earnings report.
If the price doesn't return inside the channel on Monday, the bears will be able to bring it down to the $1.73, 61.8 Fibonacci level. Moreover, the breakout of $1.73 opens the way to $1.40.
Do you want to get updates Live? Subscribe to the @FBSAnalytics Telegram Channel where I post more daily trade ideas!
The previous year 2022, was undoubtedly tumultuous for the stock markets, with several stocks plummeting across multiple industries. Analysts have blamed the hard times on inflation, hawkish federal reserve policies, an impending global recession, and the ongoing crisis in Ukraine. This year, however, we're beginning to see some recovery in the stock markets. This article will find a few stocks worth buying this year.
In a call scheduled for January 25, 00:30 am GMT+2, Microsoft will publish the company's earnings for the final quarter of 2022 and comment on the results, projections, and outlook for the nearest future of the company.
Let's dive into the latest developments shaping the global economic landscape. Good news first: the threat of an unprecedented US debt crisis has receded, as US lawmakers passed a bill to raise the debt ceiling and avoid a catastrophic default. Phew! But don't pop the champagne just yet, because storm clouds are still looming. High inflation, rising interest rates, and sluggish growth are challenges that have yet to disappear.
Thanks to the incredible advancements in horizontal drilling and fracking technology, the United States has experienced a mind-blowing shale revolution. They've become the heavyweight champion of crude oil production, leaving Saudi Arabia and Russia in the dust. They even turned the tables and became net exporters of refined petroleum products in 2011.
Let's dive into the world of gold. Currently, the price of gold, represented by XAUUSD, is stuck in indecision, hovering around the $1,975 mark. The market is anxiously awaiting two important factors: the release of the Federal Reserve's meeting minutes and the extension of the US debt ceiling.